Tag: Alzheimer’s treatment
Ethical Issues Raised Over FDA Collaboration with Biogen on Failed Drug
The FDA collaborated with Biogen to conduct repeated re-analyses of aducanumab for Alzheimer's and FDA committee members are raising concerns.
Biogen Pushes FDA to Approve Failed Alzheimer’s Drug
A new analysis, published in Lancet Neurology, demonstrates how Biogen is spinning results from two failed trials for a new Alzheimer's drug.